SAMHSA Just Put $281 Million on the Table. Read the Fine Print Before You Celebrate.
Daily Pulse: fifteen grant programs, one clear priority list, and a test-strip ban sitting three months in the rearview.
SAMHSA announced $281 million across fifteen grant programs on July 6, and the largest single line item tells you where the agency’s priorities actually sit right now: $68.2 million for Medication-Assisted Treatment for Prescription Drug and Opioid Addiction, followed by $55.7 million for Project AWARE, the school-based mental-health-crisis program, and $40.6 million for trauma-focused care through the National Child Traumatic Stress Initiative. Smaller pots follow for first responders ($34.7 million under the Comprehensive Addiction and Recovery Act), emergency departments offering opioid alternatives ($6 million), and recovery community services ($1.5 million, split across two separate funding lines that both carry the same name and will confuse every grant writer who applies to both).
HHS Secretary Robert F. Kennedy Jr. framed the announcement as part of what the administration calls the “Great American Recovery Initiative,” saying the department is “investing more than $281 million through 15 grant programs to expand treatment and equip communities.”
Money is not neutral. This round funds medication and crisis response generously and harm reduction not at all — and that’s not an oversight, it’s the same policy already on the books.
Here’s the fine print worth reading before anyone treats this as unambiguous good news: this is new grant money layered on top of an agency that, three months earlier, told every grantee that block-grant dollars can no longer buy fentanyl, xylazine, or medetomidine test strips, or sterile water and saline for injection. Nothing in the new $281 million reverses that April guidance — Medication-Assisted Treatment funding and syringe supply funding are not substitutes for each other, and a county that lost its test-strip budget in April doesn’t get it back by watching this announcement land in July. The $10.5 million “Treatment, Recovery and Workforce Support” line and the $1 million Center of Excellence for behavioral-health data protection are useful, real money. They are also a different pot than the one that used to pay for the fentanyl strips a lot of these same grantees just lost.
For facility administrators and program directors: the application windows on these fifteen programs are the thing to move on now, not later — SAMHSA didn’t publish deadlines in the July 6 announcement itself, which means the real deadline information is buried in each program’s individual Notice of Funding Opportunity on Grants.gov, and the programs that fund what your organization actually does (first responder training, MAT expansion, workforce support) are worth a same-week check rather than a someday one. Good money showing up doesn’t cancel out money that already left. Track both.
Sources Cited
- 01.A
- 02.A
Filed Under
policytrendsSAMHSA
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Schedule a Sedative by Name and the Supply Hires the Next One
Depressants are one family: alcohol, benzodiazepines, barbiturates and the newer veterinary-derived sedatives. The law sorts them by name. The supply sorts them by what works. Here's what that gap costs.
Policy & FundingThe DEA Finally Drew a Line Between Kratom Leaf and 7-OH. The Gas-Station Shelf Is About to Feel It.
DEA's October notice would place 7-OH and MGPI in Schedule I above an HHS-recommended concentration threshold, separating enhanced products from botanical kratom.
Policy & FundingHHS Found $96 Million for Eight Cities' Street Outreach While SAMHSA Stops Paying for Test Strips
HHS named eight STREETS communities on October 2 with $96 million over four years. The same agency told grantees it would stop paying for drug-checking supplies.